Nanoparticle-based radiosensitization strategies for improving radiation therapy

Hongxin Shen, Hong Huang, Zhimei JiangFrontiers in Pharmacology 2023 · DOI

Abstract

Radiotherapy remains the mainstay treatment for a variety of cancer forms. However, the therapeutic efficiency of radiation is significantly limited by several aspects, including high radiation resistance caused by low reactive oxygen species concentrations and a low absorption rate of radiation by tumor tissue, inappropriate tumor cell cycle and tumor cell apoptosis, and serious radiation damage to normal cells. In recent years, nanoparticles have been widely used as radiosensitizers due to their unique physicochemical properties and multifunctionalities for potentially enhancing radiation therapy efficacy. In this study, we systematically reviewed several nanoparticle-based radiosensitization strategies for radiation therapy use, including designing nanoparticles that upregulate the levels of reactive oxygen species, designing nanoparticles that enhance the radiation dose deposit, designing chemical drug-loaded nanoparticles for enhancing cancer cell sensitivity to radiation, designing antisense oligonucleotide gene-loaded nanoparticles, and designing nanoparticles using a unique radiation-activable property. The current challenges and opportunities for nanoparticle-based radiosensitizers are also discussed.

Introduction

Radiotherapy (RT) is a cornerstone of oncology, utilized in approximately 50% of all cancer cases. Despite its widespread use, its clinical effectiveness is often hampered by three primary hurdles: radioresistance, physical limitations in radiation absorption, and biological repair mechanisms. Tumors frequently exist in hypoxic (low-oxygen) environments, which diminishes the generation of reactive oxygen species (ROS) necessary for DNA damage. Furthermore, tumor tissue lacks a natural mechanism to absorb radiation more efficiently than healthy tissue, leading to dose-limiting toxicity. Finally, cancer cells possess robust DNA repair mechanisms that can lead to treatment resistance and recurrence.

Nanoparticle-Based Strategies for Radiosensitization

To address these challenges, researchers are developing engineered nanoparticles (NPs) that act as radiosensitizers. This review, published in Frontiers in Pharmacology, categorizes these efforts into five functional strategies:

1. ROS Upregulation

NPs can be designed to remodel the tumor microenvironment (TME) by either producing oxygen or directly generating ROS. For instance, Manganese Dioxide ($MnO_2$) NPs can react with endogenous hydrogen peroxide ($H_2O_2$) within the tumor to produce $O_2$, thereby alleviating hypoxia and providing the necessary "fuel" for radiation-induced free radical formation.

Summary of various nanoparticle types, sizes, and radiation doses used in radiosensitization studies.

2. High-Z Element Deposition

Materials with high atomic numbers (Z), such as Gold (Au), Hafnium (Hf), and Bismuth (Bi), have a high photoelectric cross-section. They absorb more radiation energy than soft tissue and release secondary electrons locally, enhancing the radiation dose deposited within the tumor.

3. Chemotherapeutic Co-delivery and Gene Therapy

NPs can serve as targeted delivery vehicles for chemotherapeutic agents or antisense oligonucleotides (ASOs). By synchronizing drug release with radiation or silencing genes responsible for DNA repair (such as ATM or EGFR), researchers can "disarm" the cancer cell's defense mechanisms, making them more susceptible to radiation damage.

4. Radiation-Activable NPs

"Smart" NPs can be engineered to remain inert until triggered by radiation. This localized activation ensures that toxic therapeutic agents are only released within the defined radiation field, further sparing healthy tissue.

Key Results and Dose Enhancement

The effectiveness of high-Z nanoparticles is governed by the photoelectric effect, which is proportional to $Z^4/E^3$. This physical principle explains why Bismuth (Z=83) is a particularly potent enhancer. Experimental data highlights the significant impact of these strategies on the Dose Enhancement Factor (DEF).

Table of High-Z element nanoparticles and their corresponding Dose Enhancement Factor (DEF) values across different cell lines.

Key benchmarks from the literature include:

  • Dose Enhancement: Bismuth oxide ($Bi_2O_3$) nanoparticles have demonstrated some of the highest reported DEF values, reaching up to 3.28 for sheet-like structures.
  • ROS Production: Selenium NPs combined with radiation have been shown to increase intracellular ROS levels to 210.2% compared to controls.
  • Clinical Progress: The field is moving toward clinical application. For example, NBTXR3 (hafnium dioxide NPs) has reached Phase III clinical trials for head and neck cancers.

Challenges and Future Directions

While promising, several challenges remain. Most NP strategies rely on the "Enhanced Permeability and Retention" (EPR) effect for tumor accumulation, which is highly variable in humans compared to animal models. Additionally, off-target accumulation in the liver, spleen, and kidneys raises concerns regarding long-term nanotoxicity. Future research must focus on "active targeting"—using ligands to bind NPs to specific tumor receptors—to improve delivery efficiency and move beyond the limitations of passive accumulation.

Summary updated

Abstract

Radiotherapy remains the mainstay treatment for a variety of cancer forms. However, the therapeutic efficiency of radiation is significantly limited by several aspects, including high radiation resistance caused by low reactive oxygen species concentrations and a low absorption rate of radiation by tumor tissue, inappropriate tumor cell cycle and tumor cell apoptosis, and serious radiation damage to normal cells. In recent years, nanoparticles have been widely used as radiosensitizers due to their unique physicochemical properties and multifunctionalities for potentially enhancing radiation therapy efficacy. In this study, we systematically reviewed several nanoparticle-based radiosensitization strategies for radiation therapy use, including designing nanoparticles that upregulate the levels of reactive oxygen species, designing nanoparticles that enhance the radiation dose deposit, designing chemical drug-loaded nanoparticles for enhancing cancer cell sensitivity to radiation, designing antisense oligonucleotide gene-loaded nanoparticles, and designing nanoparticles using a unique radiation-activable property. The current challenges and opportunities for nanoparticle-based radiosensitizers are also discussed.
BibTeX
@inproceedings{shen2023nanoparticle,
  author = {Hongxin Shen and Hong Huang and Zhimei Jiang},
  title = {{Nanoparticle-based radiosensitization strategies for improving radiation therapy}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1145551},
}
Figure